Competitive intelligence in biotech: the sources are different, the discipline is not
Clinical trial registries, patent filings, conference abstracts, and regulatory submissions. In biotech the public disclosure requirements are unusually generous, and most people still do not read them.
Biotech competitive intelligence is unusual, and the reason is regulation.
In most industries a company can keep its plans quiet. In life sciences, the law forces disclosure at multiple points, which means competitors publish things about themselves that in any other sector would be a closely held secret.
And yet most people still do not read them.
Clinical trial registries
This is the richest public source in any industry, and it is free.
Companies are required to register trials. The registration tells you the indication, the phase, the primary endpoints, the enrollment target, the sites, and the expected timeline. That is not a press release. That is a strategy document, filed under legal obligation, in a searchable database.
Watch for changes as well as new entries. A trial whose enrollment target quietly drops is a trial having trouble recruiting. A primary endpoint that gets amended mid-study is a company hedging against a result they are worried about. A trial that goes suspended and does not say why is a story.
None of that gets announced. All of it is public.
Patent filings
Patents leak direction years before anything exists, because you have to file long before you launch.
The catch is that they are written by lawyers to be legally broad rather than informatively clear, which makes them genuinely hard to read. Reading them well is a skill, and at scale it is a budget line.
But the signal is real, and it is early. A cluster of filings in a new mechanism is a company that has decided something, several years before you would learn it any other way.
Conference abstracts
The abstract deadlines are known and the abstracts are frequently public before the presentation.
This means results often become visible weeks or months before formal publication, and the sequence is predictable enough to plan around. If you know which conference matters in your area, you know roughly when your competitor's data becomes visible.
Regulatory submissions and correspondence
Depending on jurisdiction, a good deal of the back and forth between a company and a regulator becomes public, sometimes years later, sometimes not.
This is slow intelligence, but it is unusually candid, because these documents are written to a regulator rather than to a market, and the tone is completely different from anything the company says publicly.
The discipline does not change
Different sources. Same habits.
Be alerted rather than going looking, because a trial registry you check when you remember is a trial registry you will stop checking. Watch a narrow set of competitors properly rather than a wide set badly. And keep a quarterly session where you look at three months of signals together and ask what the direction is, because in biotech the timelines are long and the trend is everything.
The sources are more generous here than almost anywhere. The failure mode is exactly the same: people collect, drown, and quit.